PURPOSE: We previously found that cellular FLICE-inhibitory protein (c-FLIP), caspase 8, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (DR5) are major regulators of cell viability and chemotherapy-induced apoptosis in colorectal cancer. In this study, we determined the prognostic significance of c-FLIP, caspase 8, TRAIL and DR5 expression in tissues from patients with stage II and III colorectal cancer. EXPERIMENTAL DESIGN: Tissue microarrays were constructed from matched normal and tumor tissue derived from patients (n = 253) enrolled in a phase III trial of adjuvant 5-fluorouracil-based chemotherapy versus postoperative observation alone. TRAIL, DR5, caspase 8, and c-FLIP expression levels were determined by immunohistochemistry. RESULTS: Colorectal tumors displayed significantly higher expression levels of c-FLIP (P < 0.001), caspase 8 (P = 0.01), and DR5 (P < 0.001), but lower levels of TRAIL (P < 0.001) compared with matched normal tissue. In univariate analysis, higher TRAIL expression in the tumor was associated with worse overall survival (P = 0.026), with a trend to decreased relapse-free survival (RFS; P = 0.06), and higher tumor c-FLIP expression was associated with a significantly decreased RFS (P = 0.015). Using multivariate predictive modeling for RFS in all patients and including all biomarkers, age, treatment, and stage, we found that the model was significant when the mean tumor c-FLIP expression score and disease stage were included (P < 0.001). As regards overall survival, the overall model was predictive when both TRAIL expression and disease stage were included (P < 0.001). CONCLUSIONS: High c-FLIP and TRAIL expression may be independent adverse prognostic markers in stage II and III colorectal cancer and might identify patients most at risk of relapse.
PURPOSE: We previously found that cellular FLICE-inhibitory protein (c-FLIP), caspase 8, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (DR5) are major regulators of cell viability and chemotherapy-induced apoptosis in colorectal cancer. In this study, we determined the prognostic significance of c-FLIP, caspase 8, TRAIL and DR5 expression in tissues from patients with stage II and III colorectal cancer. EXPERIMENTAL DESIGN: Tissue microarrays were constructed from matched normal and tumor tissue derived from patients (n = 253) enrolled in a phase III trial of adjuvant 5-fluorouracil-based chemotherapy versus postoperative observation alone. TRAIL, DR5, caspase 8, and c-FLIP expression levels were determined by immunohistochemistry. RESULTS:Colorectal tumors displayed significantly higher expression levels of c-FLIP (P < 0.001), caspase 8 (P = 0.01), and DR5 (P < 0.001), but lower levels of TRAIL (P < 0.001) compared with matched normal tissue. In univariate analysis, higher TRAIL expression in the tumor was associated with worse overall survival (P = 0.026), with a trend to decreased relapse-free survival (RFS; P = 0.06), and higher tumorc-FLIP expression was associated with a significantly decreased RFS (P = 0.015). Using multivariate predictive modeling for RFS in all patients and including all biomarkers, age, treatment, and stage, we found that the model was significant when the mean tumorc-FLIP expression score and disease stage were included (P < 0.001). As regards overall survival, the overall model was predictive when both TRAIL expression and disease stage were included (P < 0.001). CONCLUSIONS: High c-FLIP and TRAIL expression may be independent adverse prognostic markers in stage II and III colorectal cancer and might identify patients most at risk of relapse.
Authors: Jörn Sträter; Ulf Hinz; Henning Walczak; Gunhild Mechtersheimer; Karin Koretz; Christian Herfarth; Peter Möller; Thomas Lehnert Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: S Hopkins-Donaldson; A Ziegler; S Kurtz; C Bigosch; D Kandioler; C Ludwig; U Zangemeister-Wittke; R Stahel Journal: Cell Death Differ Date: 2003-03 Impact factor: 15.828
Authors: Jan J Koornstra; Jan H Kleibeuker; Caroline M M van Geelen; Fleur E M Rijcken; Harry Hollema; Elisabeth G E de Vries; Steven de Jong Journal: J Pathol Date: 2003-07 Impact factor: 7.996
Authors: Yogesh M Kulkarni; Emily Chambers; A J Robert McGray; Jason S Ware; Jonathan L Bramson; David J Klinke Journal: Integr Biol (Camb) Date: 2012-07-09 Impact factor: 2.192
Authors: Robbie Carson; Basak Celtikci; Patrick G Johnston; Sandra Van Schaeybroeck; Cathy Fenning; Arman Javadi; Nyree Crawford; Lucia Perez Carbonell; Mark Lawler; Daniel B Longley Journal: Clin Cancer Res Date: 2015-03-26 Impact factor: 12.531
Authors: Teppei Morikawa; Yoshifumi Baba; Mai Yamauchi; Aya Kuchiba; Katsuhiko Nosho; Kaori Shima; Noriko Tanaka; Curtis Huttenhower; David A Frank; Charles S Fuchs; Shuji Ogino Journal: Clin Cancer Res Date: 2011-02-10 Impact factor: 12.531
Authors: E Kerr; C Holohan; K M McLaughlin; J Majkut; S Dolan; K Redmond; J Riley; K McLaughlin; I Stasik; M Crudden; S Van Schaeybroeck; C Fenning; R O'Connor; P Kiely; M Sgobba; D Haigh; P G Johnston; D B Longley Journal: Cell Death Differ Date: 2012-02-10 Impact factor: 15.828
Authors: Leanne Stevenson; Wendy L Allen; Richard Turkington; Puthen V Jithesh; Irina Proutski; Gail Stewart; Heinz-Josef Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston Journal: Clin Cancer Res Date: 2012-08-02 Impact factor: 12.531
Authors: Daniela Schmid; Francois Fay; Donna M Small; Jakub Jaworski; Joel S Riley; Diana Tegazzini; Cathy Fenning; David S Jones; Patrick G Johnston; Daniel B Longley; Christopher J Scott Journal: Mol Ther Date: 2014-07-23 Impact factor: 11.454